Inside the FDA’s Push to Update Testosterone Therapy Labels on Prostate Cancer and Blood Pressure
Federal revisions to testosterone therapy warnings may alter the landscape of TRT access, clinical prescribing practices and treatment choices for millions of people.
Federal regulators are moving to rewrite the rulebook on testosterone replacement therapy, easing warnings that have shaped how doctors prescribe the hormone for more than a decade. The shift, driven by a landmark safety trial and a broader reassessment of prostate risk, signals a coming expansion of who can access TRT and how it’s marketed. For millions of people weighing treatment, the calculus is about to change.
What’s happening with testosterone therapy labels
In June 2026, the U.S. Department of Health and Human Services, through the FDA, formally requested updates to the prescribing information for testosterone replacement therapy products. The agency said the changes follow a comprehensive review of new clinical data and existing scientific evidence.
Three proposed revisions stand out: removing the limitation of use stating that TRT’s safety and effectiveness in men with age-related hypogonadism have not been established; updating information related to prostate cancer risk; and revising warnings about benign prostatic hyperplasia, or enlarged prostate. Under the proposed language, TRT would be formally contraindicated only for men with metastatic prostate cancer.
Woman's World Answers
“As our understanding of testosterone therapy continues to evolve, prescribing information should reflect the best available science,” said Brian J. Christine, M.D., Assistant Secretary for Health. “This action helps ensure patients and healthcare providers have accurate, up-to-date information when considering treatment options.”
The 2026 proposals build on labeling changes the FDA set in motion in February 2025, when it directed sponsors to add TRAVERSE trial results to all testosterone products and remove Boxed Warning language tied to cardiovascular risk.
Why it’s happening
The single biggest driver is the TRAVERSE trial, a study of more than 5,200 men submitted to the FDA in 2023. It found that men taking TRT did not have a significant increase in the risk of serious cardiovascular events, such as heart attacks or strokes, compared with men not taking the therapy. That evidence effectively dismantled the rationale for the 2015 warning that had constrained prescribing for a decade.
A parallel force is the accumulation of prostate research. The FDA notes that clinical trials and population studies have not generally shown TRT increases prostate cancer risk — though the agency acknowledges lingering uncertainty because prostate cancer develops slowly and existing studies may not run long enough to catch late effects.
The third driver is a reassessment of enlarged prostate concerns. The FDA’s review found that available clinical trial data do not demonstrate worsening symptoms in men with mild to moderate benign prostatic hyperplasia, though evidence remains limited for men with severe symptoms.
“FDA’s responsibility is to ensure prescribing information reflects the best available scientific evidence. These updates provide patients and healthcare professionals with clearer information about the benefits and risks of testosterone replacement therapy and support informed treatment decisions.”
— Michael Davis, M.D., Ph.D., Acting Director, FDA’s Center for Drug Evaluation and Research
What could be next
The regulatory reset is likely to reshape three fronts over the next 12 to 24 months — clinical practice, the men’s-health marketplace and the safety conversation that replaces the retired warnings.
Expect a broader prescribing conversation for older men. Removing the age-related hypogonadism limitation clears a friction point that has made many primary care doctors hesitant to prescribe TRT to men whose low testosterone tracks with aging rather than a specific medical trigger. As Cleveland Clinic explains, the FDA has historically approved TRT only for men with low testosterone tied to a known medical condition. That posture is softening. If you’re a man over 50 with symptoms — fatigue, low libido, mood changes — and previously bounced off a “not FDA-approved for your situation” conversation, it’s worth revisiting with a physician once revised labeling is finalized. Ask specifically whether the updated prescribing information changes your candidacy.
Anticipate a marketing surge from telehealth men’s-health clinics. The direct-to-consumer TRT space has grown aggressively during the era of restrictive labeling. A relaxed FDA posture will hand these platforms new advertising latitude, particularly around age-related low T. Readers considering online prescribers should watch for whether providers still require lab confirmation of low testosterone, prostate screening before treatment and ongoing monitoring, all of which the FDA continues to recommend. A clinic that skips those steps is not following the science the new labels are built on.
Watch blood pressure become the new headline risk. As cardiovascular warnings recede, the elevated-blood-pressure warning added in February 2025 becomes the most concrete class-wide safety flag. The FDA’s ambulatory blood pressure monitoring studies confirmed testosterone products as a class raise blood pressure. Men starting or continuing TRT should ask their prescriber to establish a blood pressure baseline and set a monitoring schedule. This is the risk that has quietly moved to the front of the label.
The through-line: TRT is transitioning from a therapy hemmed in by a heart-attack warning to one governed by a more nuanced risk profile — cardiovascular fears down, blood pressure and prostate monitoring up, access likely wider. The clear takeaway for readers is that “low T” is about to become a more open medical conversation, and the responsibility for asking sharp questions about screening and monitoring shifts more squarely onto the patient.
THREE SIGNALS TO WATCH
1. Publication of the final revised FDA prescribing information for testosterone products following the June 2026 request.
2. Manufacturer label updates adding TRAVERSE trial results and the new blood pressure warning across all testosterone products.
3. Expanded telehealth advertising for age-related low testosterone as the “age-related hypogonadism” limitation of use is lifted.
Conversation
All comments are subject to our Community Guidelines. Woman's World does not endorse the opinions and views shared by our readers in our comment sections. Our comments section is a place where readers can engage in healthy, productive, lively, and respectful discussions. Offensive language, hate speech, personal attacks, and/or defamatory statements are not permitted. Advertising or spam is also prohibited.
